Free Trial

20 "Past Their Prime" Stocks to Dump From Your Portfolio - 16 of 20

 
 

Roivant Sciences (NASDAQ:ROIV)

Roivant Sciences logoRoivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. Read More 
 
Trailing Twelve Months EPS: $5.65
2024 EPS Estimate: ($1.14)
2025 EPS Estimate: ($1.25)

Current Stock Price
$11.20
P/E Ratio
2.0
Consensus Rating
Moderate Buy
Ratings Breakdown
7 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$17.93 (60.1% Upside)

 

Let’s be blunt (Ad)

Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)!

Check out the $100 Challenge now